# Notice of References Cited

Application/Control No. 10/690,199	Reexamination	Applicant(s)/Patent Under Reexamination ASTSATUROV ET AL.		
Examiner	Art Unit			
Wu-Cheng Winston Shen	1632	Page 1 of 2		

### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	Α	US-5,942,235	08-1999	Paoletti, Enzo	424/232.1
*	В	US-6,045,802	04-2000	Schlom et al.	424/199.1
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	2					
	0					
	P					-
	Q					
	R					
	S					
	Т					

### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Miller and Vile, Targeted vectors for gene therapy, FASEB J. 9(2): 190-9, 1995
	٧	Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, Exp. Opin. Ther. Patents 8(1): 53-69, 1998; Ashley Publications Ltd. ISSN 1354-3776
	w	Verma and Somia, Gene therapy promises, problems and prospects, Nature 389: 239-42, 1997
	x	Crystal, Transfer of genes to humans: early lessons and obstacles to success, Science 270: 404-10, 1995

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

# Notice of References Cited

Application/Control No. 10/690,199	Reexamination	Applicant(s)/Patent Under Reexamination ASTSATUROV ET AL.		
Examiner	Art Unit			
Wu-Cheng Winston Shen	1632	Page 2 of 2		

### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			-
	F	US-			
	G	US-			
	н	US-			
	1	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν					
	0					
	ρ					
	Q					
	R					
	s					
	Т					

### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Pouton and Seymour, Key issues in non-viral gene delivery, Adv Drug Deliv Rev. 46(1-3): 187-203, 2001
0.1	v	Read et al., Barriers to gene delivery using synthetic vectors, Adv Genet. 53: 19-46, 2005
	w	Dobson, Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery.  Gene Ther. 13(4): 283-7, 2006
	×	Kirkwood et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 19(9): 2370-80, 2001

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.